Molecure Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Marcin Szumowski
Chief executive officer
zł473.2k
Total compensation
CEO salary percentage | n/a |
CEO tenure | no data |
CEO ownership | 0.7% |
Management average tenure | 4yrs |
Board average tenure | 3yrs |
Recent management updates
Recent updates
CEO
Marcin Szumowski
no data
Tenure
zł473,205
Compensation
Dr. Marcin Jan Szumowski, Ph D., is employed at Life Science Innovations Fund. He has been Chief Executive Officer and President of the Management Board at Molecure S.A. (formerly known as OncoArendi Thera...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | no data | zł473.21k | 0.70% € 269.0k | |
CFO & Member of the Management Board | no data | zł421.09k | 0.20% € 79.2k | |
Chief Scientific Officer & Member of Management Board | 3yrs | zł473.21k | 0.11% € 43.4k | |
Member of Management Board & HR Director | 5yrs | zł348.41k | 0.034% € 13.3k | |
Co-Founder & VP of Research Chemistry | 13yrs | zł500.00k | 3.01% € 1.2m | |
Co-Founder & Head of Medicinal Chemistry | no data | no data | no data | |
Chief Medical Officer & Member of Management Board | less than a year | no data | no data | |
Head of CMC | 5yrs | no data | no data | |
Director of the Management Board Office | 3yrs | no data | no data |
4.0yrs
Average Tenure
Experienced Management: 1B1's management team is considered experienced (4 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Vice Chairman of the Supervisory Board | 5yrs | zł133.62k | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Chairman of the Supervisory Board | 3yrs | zł132.99k | 0.059% € 23.0k | |
Independent Member of the Supervisory Board | 3yrs | zł124.22k | no data | |
Member of the Supervisory Board | 1.5yrs | zł44.45k | no data | |
Independent Member of the Supervisory Board | 2.6yrs | zł124.22k | no data |
3.0yrs
Average Tenure
Experienced Board: 1B1's board of directors are considered experienced (3 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/06 04:58 |
End of Day Share Price | 2025/01/03 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Molecure S.A. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Kamil Kliszcz | Biuro maklerskie mBanku |
Beata Szparaga-Wasniewska | Biuro maklerskie mBanku |
Lukasz Kosiarski | Ipopema Securities S.A. |